




The relative strengths and weaknesses of Pharmacyclics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Pharmacyclics INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 104% points. The greatest weakness of Pharmacyclics INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 39% points.

The company's Economic Capital Ratio, given in the ranking table, is 343%, being 123% points above the market average of 220%.

Input Variable	Value in 1000 USD
Assets, Current	346,492
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	29,257
Liabilities, Non-Current	0
Other Assets	2,234
Other Compr. Net Income	12
Other Expenses	39
Other Liabilities	63,346
Other Net Income	147
Other Revenues	81,990
Property and Equipment	6,403
Research and Development	54,537
Selling, General and Administrative Expense	15,575

Output Variable	Value in 1000 USD
Assets	355,129
Liabilities	92,603
Expenses	70,151
Revenues	81,990
Stockholders Equity	262,526
Net Income	11,986
Comprehensive Net Income	11,992
BaseVar	300,016
ECR before LimitedLiability	261%
Economic Capital Ratio	343%